Concordia International Corp. | CIK:0001642271 | 3

  • Filed: 3/8/2018
  • Entity registrant name: Concordia International Corp. (CIK: 0001642271)
  • Generator: Workiva (WebFilings)
  • SEC filing page: http://www.sec.gov/Archives/edgar/data/1642271/000164227118000008/0001642271-18-000008-index.htm
  • XBRL Instance: http://www.sec.gov/Archives/edgar/data/1642271/000164227118000008/cxrx-20171231.xml
  • XBRL Cloud Viewer: Click to open XBRL Cloud Viewer
  • EDGAR Dashboard: https://edgardashboard.xbrlcloud.com/edgar-dashboard/?cik=0001642271
  • Open this page in separate window: Click

    • ifrs-full:DisclosureOfImpairmentOfAssetsExplanatory

    Details of significant impairments were as follows:
     
    Impairment
    Remaining Carrying Value as at Jun 30, 2017
    Liothyronine Sodium
    128,191

    53,969

    Fusidic Acid
    83,263

    64,956

    Prednisolone
    41,679

    16,554

    Nefopam
    17,353

    3,944

    Alimemazine Tartrate
    11,185

    8,026

    Prochlorperazine Mesilate
    7,217

    5,164

    Dicycloverine
    5,060

    10,687

    For the remaining products the Company recorded impairments using a fair value less costs of disposal model in the statement of loss for the year ended December 31, 2016. The impairments recorded during the fourth quarter of 2016 and the resulting carrying values subsequent to the impairments were as follows:
     
    Impairment
    Remaining Carrying Value as at Dec 31, 2016
    Plaquenil®
    219,354

    47,089

    Uroxatral®
    38,544

    20,567

    Dyrenium®
    23,056

    19,621

    Dibenzyline®
    10,518

    33,342

    Parnate®
    8,009

    7,225

    Ulesfia®
    7,457

    —

    The total impairment recorded on acquired product rights during the fourth quarter of 2017 was $124,899. Details of significant impairments were as follows:
     
    Impairment
    Remaining Carrying Value as at Dec 31, 2017
    Erythromycin
    17,249

    23,888

    Cyclizine Hcl
    17,084

    41,634

    Prednisolone
    11,141

    4,934

    Trazodone
    7,271

    3,771

    Ergotamine + Caffeine
    6,084

    7,037

    Dipipanone + Cyclizine
    4,373

    12,603

    Hydralazine Hcl
    4,094

    8,974

    Details of significant impairments were as follows:
     
    Impairment
    Remaining Carrying Value as at Dec 31, 2016
    Levothyroxine Sodium
    61,594

    90,159

    Prednisolone
    43,521

    58,738

    Hydrocortisone
    26,129

    8,042

    Carbimazole
    12,088

    63,471

    Tranylcypromine Sulphate
    13,379

    13,537

    Dicycloverine
    11,835

    15,883

    Dipipanone Cyclizine
    9,904

    17,696

    Nefopam
    8,306

    21,479